Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Pc945
2. Opelconazole(inn)
3. 1931946-73-4
4. Opelconazole [usan]
5. Pc-945
6. Unii-45lu8q6asu
7. 45lu8q6asu
8. D-threo-pentitol, 2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-((4-(4-(4-(((4-fluorophenyl)amino)carbonyl)phenyl)-1-piperazinyl)-2-methylphenoxy)methyl)-1-(1h-1,2,4-triazol-1-yl)-
9. Chembl4650362
10. Schembl17807161
11. Glxc-25375
12. Who 11612
13. Hy-117766
14. Cs-0067758
15. (62 R,64 R)-62 -(2,4-difluorophenyl)-n-(4-fluorophenyl)-33 - Methyl-4-oxa-2(1,4)-piperazina-8(1)-(1,2,4)triazola6(4,2)-oxolana-1(1),3(1,4)-dibenzenaoctaphane-14 - Carboxamide
16. 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-n-(4-fluorophenyl)benzamide
17. 4-[4-[4-[[(3r,5r)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]-3-methylphenyl]piperazin-1-yl]-n-(4-fluorophenyl)benzamide
| Molecular Weight | 682.7 g/mol |
|---|---|
| Molecular Formula | C38H37F3N6O3 |
| XLogP3 | 6.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 10 |
| Exact Mass | 682.28792355 g/mol |
| Monoisotopic Mass | 682.28792355 g/mol |
| Topological Polar Surface Area | 84.8 Ų |
| Heavy Atom Count | 50 |
| Formal Charge | 0 |
| Complexity | 1090 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
PC945 (opelconazole), is a potent novel azole therapy specifically designed for inhaled use to maximize the amount of drug in the lung while providing minimal systemic exposure.
Lead Product(s): Opelconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: PC945
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Lead Product(s) : Opelconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pulmocide Reports Successful Results from OPERA-S Phase 2 Safety Study with Opelconazole
Details : PC945 (opelconazole), is a potent novel azole therapy specifically designed for inhaled use to maximize the amount of drug in the lung while providing minimal systemic exposure.
Brand Name : PC945
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 15, 2024
Details:
PC945 (opelconazole), is a potent novel azole therapy specifically designed for inhaled use to maximize the amount of drug in the lung while providing minimal systemic exposure.
Lead Product(s): Opelconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: PC945
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Lead Product(s) : Opelconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PC945 (opelconazole), is a potent novel azole therapy specifically designed for inhaled use to maximize the amount of drug in the lung while providing minimal systemic exposure.
Brand Name : PC945
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 16, 2023
Details:
Pulmocide’s opelconazole is a potent novel azole therapy specifically designed for inhaled use to maximize the amount of drug in the lung while providing minimal systemic exposure.
Lead Product(s): Opelconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: PC945
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Pictet Alternative Advisors
Deal Size: $147.5 million Upfront Cash: Undisclosed
Deal Type: Series C Financing December 06, 2022
Lead Product(s) : Opelconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pictet Alternative Advisors
Deal Size : $147.5 million
Deal Type : Series C Financing
Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole
Details : Pulmocide’s opelconazole is a potent novel azole therapy specifically designed for inhaled use to maximize the amount of drug in the lung while providing minimal systemic exposure.
Brand Name : PC945
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 06, 2022
Details:
The CF Foundation’s funding will support Phase 2 study of opelconazole. The objective of the study is to assess the safety and tolerability and patient’s ability to complete the course of treatment when used to prevent invasive pulmonary fungal infections in lung transplant.
Lead Product(s): Opelconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: PC945
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Cystic Fibrosis Foundation
Deal Size: $3.5 million Upfront Cash: Undisclosed
Deal Type: Funding December 06, 2021
Lead Product(s) : Opelconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Cystic Fibrosis Foundation
Deal Size : $3.5 million
Deal Type : Funding
Details : The CF Foundation’s funding will support Phase 2 study of opelconazole. The objective of the study is to assess the safety and tolerability and patient’s ability to complete the course of treatment when used to prevent invasive pulmonary fungal infec...
Brand Name : PC945
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 06, 2021
Details:
Pulmocide’s lead product is opelconazole (PC945), a novel antifungal therapy specifically designed for inhaled use to maximize the amount of drug in the lung and spare systemic exposure.
Lead Product(s): Opelconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: PC945
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
Lead Product(s) : Opelconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pulmocide’s Lead Drug Candidate Opelconazole Granted Orphan Drug, Fast Track and Qualified Infec...
Details : Pulmocide’s lead product is opelconazole (PC945), a novel antifungal therapy specifically designed for inhaled use to maximize the amount of drug in the lung and spare systemic exposure.
Brand Name : PC945
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 15, 2021
Details:
Proceeds from the financing will primarily be used to advance the Company’s lead asset PC945 through a global Phase III registration program in patients with invasive pulmonary aspergillosis (IPA) who have failed prior therapy.
Lead Product(s): Opelconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: PC945
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Jeito Capital
Deal Size: $92.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 27, 2021
Lead Product(s) : Opelconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Jeito Capital
Deal Size : $92.0 million
Deal Type : Series C Financing
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
Details : Proceeds from the financing will primarily be used to advance the Company’s lead asset PC945 through a global Phase III registration program in patients with invasive pulmonary aspergillosis (IPA) who have failed prior therapy.
Brand Name : PC945
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 27, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Opelconazole manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Opelconazole, including repackagers and relabelers. The FDA regulates Opelconazole manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Opelconazole API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Opelconazole supplier is an individual or a company that provides Opelconazole active pharmaceutical ingredient (API) or Opelconazole finished formulations upon request. The Opelconazole suppliers may include Opelconazole API manufacturers, exporters, distributors and traders.
Opelconazole Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Opelconazole GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Opelconazole GMP manufacturer or Opelconazole GMP API supplier for your needs.
A Opelconazole CoA (Certificate of Analysis) is a formal document that attests to Opelconazole's compliance with Opelconazole specifications and serves as a tool for batch-level quality control.
Opelconazole CoA mostly includes findings from lab analyses of a specific batch. For each Opelconazole CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Opelconazole may be tested according to a variety of international standards, such as European Pharmacopoeia (Opelconazole EP), Opelconazole JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Opelconazole USP).
LOOKING FOR A SUPPLIER?
